We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

185 hedge funds and large institutions have $1.91B invested in Pacira BioSciences in 2017 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 76 increasing their positions, 52 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more call options, than puts

Call options by funds: $26.7M | Put options by funds: $14.8M

46% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 52

20% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 30

16% more capital invested

Capital invested by funds: $1.64B → $1.91B (+$268M)

3% more funds holding

Funds holding: 180 → 185 (+5)

5.17% less ownership

Funds ownership: 108.44% → 103.26% (-5.2%)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

Holders
185
Holders Change
+5
Holders Change %
+2.78%
% of All Funds
4.2%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.11%
New
36
Increased
76
Reduced
52
Closed
30
Calls
$26.7M
Puts
$14.8M
Net Calls
+$11.9M
Net Calls Change
-$18.5M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$21.4M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$15.1M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$12.4M
4
CCM
Consonance Capital Management
New York
+$8.81M
5
HM
HealthCor Management
New York
+$8.8M

Top Sellers

Rank Fund Capital Flow
1
WRF
Waddell & Reed Financial
Kansas
-$30.6M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$23.1M
3
ACA
Avoro Capital Advisors
New York
-$18.3M
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$15.6M
5
SI
Standard Investments
New York
-$15M
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
126
Squarepoint
New York
$488K +$423K +10,680 New
Barclays
127
Barclays
United Kingdom
$473K -$301K -7,595 -42%
JG
128
Jefferies Group
New York
$470K -$116K -2,939 -22%
PP
129
Paloma Partners
Connecticut
$452K +$392K +9,903 New
WVP
130
Worth Venture Partners
New Jersey
$436K +$379K +9,557 New
MSU
131
Mizuho Securities USA
New York
$425K +$63.4K +1,600 +21%
KeyBank National Association
132
KeyBank National Association
Ohio
$384K +$333K +8,411 New
ARTA
133
A.R.T. Advisors
New York
$378K +$329K +8,300 New
BNP Paribas Financial Markets
134
BNP Paribas Financial Markets
France
$377K +$139K +3,495 +73%
CG
135
Cutler Group
California
$360K -$144K -3,640 -32%
PNC Financial Services Group
136
PNC Financial Services Group
Pennsylvania
$357K +$1.94K +49 +0.6%
SW
137
SVB Wealth
Massachusetts
$307K +$2.97K +75 +1%
PCM
138
Piermont Capital Management
Missouri
$297K -$14.3K -360 -5%
OAM
139
Oppenheimer Asset Management
New York
$277K – – –
HighTower Advisors
140
HighTower Advisors
Illinois
$275K – – –
Parallax Volatility Advisers
141
Parallax Volatility Advisers
California
$272K +$236K +5,964 New
Baird Financial Group
142
Baird Financial Group
Wisconsin
$264K -$1.39K -35 -0.6%
AB
143
Amalgamated Bank
New York
$244K +$212K +5,340 New
Fisher Asset Management
144
Fisher Asset Management
Washington
$241K +$209K +5,282 New
AP
145
AHL Partners
United Kingdom
$241K +$209K +5,284 New
RG
146
Redmile Group
California
$237K +$206K +5,190 New
SMG
147
Spectrum Management Group
Indiana
$211K +$7.93K +200 +5%
CSS
148
Cubist Systematic Strategies
Connecticut
$211K +$84.5K +2,133 +85%
TFCP
149
Twin Focus Capital Partners
Massachusetts
$206K +$179K +4,516 New
BFG
150
Bouchey Financial Group
New York
$205K +$178K +4,500 New
4 5
6
7 8

PCRX Hedge Fund Activity: Q4 2017 in Review

185 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2017, worth a combined $1.91B — up 16% from $1.64B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new PCRX positions and 30 closed out — a net gain of 6 holders — while 76 added to existing stakes and 52 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $21.4M. The largest seller was Waddell & Reed Financial, exiting entirely with an estimated $30.6M sold.

  • 185 institutional investors held Pacira BioSciences (PCRX) as of Q4 2017, up from 180 in Q3 2017.
  • Funds reported $1.91B of Pacira BioSciences stock for Q4 2017, up 16% quarter-over-quarter.
  • 36 funds opened new Pacira BioSciences positions in Q4 2017 and 30 closed out, a net change of +6 holders.
  • The largest Pacira BioSciences buyer in Q4 2017 was Millennium Management, an estimated $21.4M added.
  • The largest Pacira BioSciences seller in Q4 2017 was Waddell & Reed Financial, an estimated $30.6M sold.

Based on aggregated 13F filings for Q4 2017.